Study of BGC515 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of advanced cancer (like mesothelioma, EHE, or another solid tumor) that has not responded to standard treatment
- You are able to take care of yourself (ECOG performance score 0 or 1)
- You have at least one tumor that can be measured on scans
- You have not taken a TEAD inhibitor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This trial tests an experimental drug called TYK-01054 for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a specific cell pathway (Hippo) that may help slow or stop tumor growth.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.